HBOT Conversations:
Dr. Paul Harch & 8,101 Genes
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on 8,101 genes is the eighth in a nine episode series that will be released weekly with Dr. Harch.
Watch the Podcast
In episode 8 of 9, host Edward di Girolamo speaks with world renowned HBOT expert, Dr. Paul G. Harch, about aging and the 8,101 genes HBOT affects.
di Girolamo starts this conversation with Dr. Harch bringing up the 8,101 genes that are activated by Hyperbaric Oxygen Therapy. The discussion leads to talk of Big Pharma, telomeres, reparative gene process, patents, and successful business models for HBOT clinics.
Dr. Harch explains that Hyperbaric Oxygen Therapy affects 8,101 of our genes, and it’s doing so on a different level for the ones that are overactive and abnormal in the disease process. He speaks of a 2004 lecture he gave to A4M about the effects of HBOT on longevity; and asks, “Where is senescence and aging based?”, answering with, “It’s in our DNA”. Dr. Harch dives in to how HBOT turns on our genes to grow new tissue and stimulates cellular repair and regeneration. di Girolamo agrees and brings up a different past lecture from Dr. Harch where Harch referred to Hyperbaric Oxygen Therapy as the ‘Fountain of Youth‘.
This series ends with Dr. Harch discussing a Buffalo VA study, and how the study subjects (comprised of older veterans) literally came alive and started propositioning nurses after Hyperbaric Oxygen Therapy treatments. He explained this is why no follow-up study was ever done because they weren’t expecting such and didn’t know what to do. Makes sense…. studies have shown success in HBOT treating erectile dysfunction.
If you are searching for the Fountain of Youth and ready to activate 8,101 genes in your body —- find a Hyperbaric Oxygen Therapy clinic near you.
Subscribe Now, It’s Free!
Guest
Dr. Paul G. Harch, MD
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Recent HBOT News
Rehabilitation of the patients with osteoarthritis.
Under the term “osteoarthritis” (OA) is currently meant a clinical syndrome resulting from the combined effect of articular pain and disordered functional activity leading to the deterioration of the quality of life of the patients. The principal objective of rehabilitation of the patients presenting with GA in which all patients with this condition are in need practically after each next aggravation of the pathological process is to relive pain syndrome and restore the functional ability of the joints lost or deteriorated after each exacerbation in order to eventually improve the quality of life of the patients experiencing the constantly progressing degenerative process in the musculoskeletal system.
A rare case of primary necrotising fasciitis of the breast: combined use of hyperbaric oxygen and negative pressure wound therapy to conserve the breast. Review of literature.
Abstract: Necrotising fasciitis is a rare but potentially fatal disease. It is even more unusual as a primary disease of the breast. Surgical treatment is required in order to gain control over the spreading infection and mastectomy is reported to be the most common...
Clinical Trial – Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
This is a pilot study to evaluate the efficacy of hyperbaric oxygen therapy (HBO2) for
mobilizing hematopoietic progenitor cells from bone marrow to blood. These cells are needed
for patients to undergo bone marrow transplantation and some patients fail to respond to
current best chemotherapy. HBO2 has been shown to trigger stem cell mobilization in other
patient populations and we plan to investigate whether this intervention can act in concert
with chemotherapeutic agents to allow poor mobilizer patients to achieve successful bone
marrow transplantation. Twenty patients will be identified by participating hematologists who
have failed to respond adequately to chemotherapy. When it is deemed appropriate to attempt
an additional stem cell mobilization protocol, these patients will be administered
chemotherapy as determined by their primary treating hematologist and additionally receive
daily HBO2 (2.5 atmospheres absolute [ATA] for 90 minutes) for 3-8 days. At intervals, blood
samples will be obtained as is the normal transplantation protocol practice to assess whether
adequate stem cells are present in blood for the patient to proceed with transplantation. The
project is anticipated to take one year to complete.